Related Experiment Video
Updated: Jul 8, 2026
MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells
Published on: December 21, 2011
Cloning and functional characterization of the HRASLS2 gene
R-Y Shyu1, Y-C Hsieh, F-M Tsai
1Department of Internal Medicine, Buddhist Tzu Chi General Hospital, Taipei Branch, Sindian, Taipei, Taiwan, Republic of China.
Abstract:
The HRAS-like suppressor 2 (HRASLS2) gene belongs to the H-REV107 gene family involved in the regulation of cell growth and differentiation. HRASLS2 is expressed at high levels in normal tissues of the small intestine, kidney, and trachea. We cloned HRASLS2 cDNA from human SW480 colon cancer cells. Most wild-type, and some N- and C-terminal truncated HRASLS2 (HRASLS2DeltaNDeltaC) were expressed as a granular pattern located at perinuclear region in HtTA cervical cancer cells, while truncation at the C-terminus only (HRASLS2DeltaC) resulted in a diffuse pattern. Wild-type HRASLS2 significantly suppressed colony formation of HeLa and HCT116 cells. HRASLS2DeltaNDeltaC significantly inhibited colony formation of HCT116 cells, but HRASLS2DeltaC did not affect cell growth. HRASLS2 suppressed the RAS-GTP levels and total RAS protein by 44% and 25%, respectively in HtTA cells; however, the suppression was not observed in truncated HRASLS2 variants. In conclusion, the HRASLS2 protein suppressed growth and RAS activities of cancer cells, and the C-terminal hydrophobic domain appeared to be indispensable for both activities.
Insights
The HRASLS2 gene suppresses cancer cell growth by inhibiting RAS protein activity. Its C-terminal domain is crucial for these tumor suppressor functions.
Area of Science:
- Molecular Biology
- Cancer Research
- Cell Biology
Background:
- The HRASLS2 gene, part of the H-REV107 family, regulates cell growth and differentiation.
- HRASLS2 exhibits high expression in normal small intestine, kidney, and trachea tissues.
- This study investigates the role of HRASLS2 in cancer, specifically colon cancer.
Purpose of the Study:
- To clone and characterize the HRASLS2 gene from human colon cancer cells.
- To investigate the subcellular localization and growth-suppressive functions of HRASLS2 and its variants.
- To determine the effect of HRASLS2 on RAS protein activity in cancer cells.
Main Methods:
- Cloning of HRASLS2 cDNA from SW480 colon cancer cells.
- Expression and localization studies of wild-type and truncated HRASLS2 in HtTA cervical cancer cells.
- Colony formation assays in HeLa and HCT116 cancer cells to assess growth inhibition.
- Measurement of RAS-GTP levels and total RAS protein in HtTA cells.
Main Results:
- Wild-type HRASLS2 and a N-/C-terminal truncated variant (HRASLS2DeltaNDeltaC) showed perinuclear localization, while C-terminal truncation (HRASLS2DeltaC) resulted in diffuse localization.
- Wild-type HRASLS2 significantly suppressed colony formation in HeLa and HCT116 cells.
- HRASLS2DeltaNDeltaC inhibited HCT116 colony formation, but HRASLS2DeltaC did not affect cell growth.
- HRASLS2 suppressed RAS-GTP levels by 44% and total RAS protein by 25% in HtTA cells, effects not seen with truncated variants.
Conclusions:
- The HRASLS2 protein effectively suppresses cancer cell growth and RAS activity.
- The C-terminal hydrophobic domain of HRASLS2 is essential for its growth-suppressive and RAS-inhibiting functions.
- HRASLS2 represents a potential therapeutic target for cancers driven by RAS pathway activation.
